# EDGAR Filing Document

**Accession Number:** 0001351172
**File Stem:** 0000950170-23-000332
**Filing Date:** 2023-1
**Character Count:** 19795
**Document Hash:** fd7bc947fd852dcf4ca15d0dd825d9b0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-000332.hdr.sgml**: 20230106

**ACCESSION NUMBER**: 0000950170-23-000332

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 23

**CONFORMED PERIOD OF REPORT**: 20230106

**FILED AS OF DATE**: 20230106

**DATE AS OF CHANGE**: 20230106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Liminal BioSciences Inc.
- **CENTRAL INDEX KEY:** 0001351172
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39131
- **FILM NUMBER:** 23515173

**BUSINESS ADDRESS:**
- **STREET 1:** 231 DUNDAS STREET EAST
- **CITY:** BELLEVILLE
- **STATE:** A6
- **ZIP:** K8N 1E2
- **BUSINESS PHONE:** 450-781-0115

**MAIL ADDRESS:**
- **STREET 1:** 440 ARMAND-FRAPPIER BLVD.
- **STREET 2:** SUITE 300
- **CITY:** LAVAL
- **STATE:** A8
- **ZIP:** H7V 4B4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ProMetic Life Sciences Inc
- **DATE OF NAME CHANGE:** 20060126

**UNITED STATES SECURITIES**

**AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the Month of January 2023**

**Commission File Number: 001-39131**

**LIMINAL BIOSCIENCES INC.**

**(Translation of registrant's name into English)**

------

**440 Armand-Frappier Boulevard, Suite 300**

**Laval, Québec**

**H7V 4B4**

**(Address of principal executive office)**

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: ☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

**<u>INCORPORATION BY REFERENCE</u>**

This Report on Form 6-K (the "Report") and Exhibit 99.1 to this Report are hereby expressly incorporated by reference into the registrant's registration statements on Form F-3 (File nos. 333-251055, 333-245703 and 333-251065) filed with the Securities and Exchange Commission on December 1, 2020, December 2, 2020 and December 2, 2020, respectively, and the registration statement on Form S-8 (File no. 333-235692) filed with the Securities and Exchange Commission on December 23, 2019.

**<u>EXHIBIT LIST</u>**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [<u>Corporate Presentation, January 2023</u>](lmnl-ex99_1.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Liminal BioSciences Inc.** | **Liminal BioSciences Inc.** | **Liminal BioSciences Inc.** |
| Date: January 6, 2023 | By: | /s/ Bruce Pritchard | /s/ Bruce Pritchard |
|  |  | Name | Bruce Pritchard |
|  |  | Title: | Chief Executive Officer |

---

------

## Exhibit 99.1

![Slide 1](lmnl-ex99_1s1.jpg)

Aiming to develop Best/First-In-Class Novel Small Molecule Therapeutics for Inflammatory, Metabolic and Fibrotic Diseases Corporate Presentation NASDAQ: LMNL January 2023 Exhibit 99.1

------

![Slide 2](lmnl-ex99_1s2.jpg)

Safe Harbour This presentation contains forward-looking statements about Liminal BioSciences' objectives, strategies and businesses that involve risks and uncertainties. Forward-looking information includes statements concerning, among other things, the Company's ability to regain compliance with the Nasdaq listing requirements, streamline its business, divest its non-core assets, advancement of Liminal Biosciences' product candidates, the outcome of anticipated clinical trials; the analysis of our clinical trial data; the potential development of Liminal Biosciences' R&D programs; the properties of our drug candidates; the timing of initiation or nature of preclinical and clinical trials and potential therapeutic areas. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Among the factors that could cause actual results to differ materially from those described or projected herein include, but are not limited to, risks associated with: the Company's ability to develop, manufacture, and successfully commercialize product candidates, if ever; the impact of the COVID-19 pandemic on the Company's workforce, business operations, clinical development, regulatory activities and financial and other corporate impacts; the availability of funds and resources to pursue R&D projects, manufacturing operations or commercialization activities; the successful and timely initiation or completion of clinical trials; the ability to take advantage of financing opportunities or business opportunities in the pharmaceutical industry; the Company's ability to resolve the Nasdaq listing deficiency and regain compliance with the Nasdaq Listing Rules; uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals; and general changes in economic conditions. You will find a more detailed assessment of these risks, uncertainties and other risks that could cause actual events or results to materially differ from our current expectations in the filings and reports the Company makes with the U.S. Securities and Exchange Commission and Canadian Securities Administrators, including in the Annual Report on Form 20-F for the year ended December 31, 2021, as well as other filings and reports Liminal Biosciences' may make from time to time. Such risks may be amplified by the ongoing COVID-19 pandemic and any related impacts on Liminal BioSciences' business and the global economy. As a result, we cannot guarantee that any given forward-looking statement will materialize. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. We assume no obligation to update any forward-looking statement contained in this presentation even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. Copyright notice The information contained in this presentation (including names, images, logos and descriptions portraying Liminal BioSciences' products and/or services) is the property of Liminal BioSciences Inc., of its divisions and / or of its subsidiaries ("Liminal") and is protected by copyright, patent and trademark law and / or other intellectual property rights. Neither this presentation nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including printing and photocopying, or by any information storage or retrieval system without prior permission in writing from Liminal. Disclaimer Liminal BioSciences reserves the right to make improvements, corrections and/or changes to this presentation at any time. 2

------

![Slide 3](lmnl-ex99_1s3.jpg)

Aiming to develop proprietary, novel, best/first in class novel small molecule therapeutics for inflammatory, metabolic and fibrotic diseases Liminal Introduction Pipeline is positioned to deliver multiple value catalysts in 2023/2024 Intellectual property (IP) all under the control of Liminal BioSciences Progressing diverse pipeline: GPR84 antagonist OXER1 antagonist Potential development opportunities from in-house drug discovery platform Experienced leadership team committed to excellence, innovation, and scientific rigor in our research and clinical development backed by our data driven philosophy Access to NASDAQ Market: LMNL

------

![Slide 4](lmnl-ex99_1s4.jpg)

LMNL is led by a strong, experienced team with proven track records in the discovery, development, and approval of biopharmaceuticals, all driven to make a difference. Management Team Bruce Pritchard Chief Executive Officer Executive Finance Positions: Prometic Life Sciences Inc., CV Therapeutics Inc., Ardana Biosciences Ltd., Director & Chair of Audit Committee Porton BioPharma, Immediate Past-President ICAS Jeffrey Smith MD Strategic Medical Adviser Founder & Managing Director, Alder Biopharmaceuticals Inc. Senior Vice President, Alder Biopharmaceuticals Inc. Dr. Gary Bridger Board Member and Interim Chief Scientific Officer Executive Vice President of R&D, Xenon Pharmaceuticals Inc. Senior Vice President of R&D, Genzyme Corporation, Co-founder & Chief Scientific Officer, AnorMED Inc. Nicole Rusaw Chief Financial Officer Chief Financial Officer and Director Klinik Health Ventures Corp. Interim Chief Financial Officer, Nuvo Pharmaceuticals Inc. Chief Financial Officer, Transition Pharmaceuticals Inc. Previous Experience Name & Title 4

------

![Slide 5](lmnl-ex99_1s5.jpg)

At Liminal, we are focused on elucidating compelling biological mechanisms and plan to advance a pipeline of small molecule therapeutics with best/first-in-class potential across a range of clinical indications with significant commercial prospects. Compelling Biological Mechanisms Data-Driven. Dedicated. We focus on molecules with proprietary IP, comprehensive preclinical evaluation and optimized clinical development. We are pursuing indications with high unmet needs and promising market and partnering/licensing potential. Rigorous Objective Approach With an improved balance sheet, we are focused on value creation for patients, our shareholders, and our employees as we strive to advance multiple assets into clinical development with a cash runway sufficient to achieve these goals. Value Creation Strategy Aimed at Best or First in Class Drug Discovery & Development

------

![Slide 6](lmnl-ex99_1s6.jpg)

Drive pipeline to quickly advance multiple assets into the clinic Seek opportunities to drive liquidity and trading in the stock Develop a pipeline of candidates for commercially viable target indications Our Driving Force Our aim is to rebuild value through four key drivers. Extend cash as non-dilutively as possible

------

![Slide 7](lmnl-ex99_1s7.jpg)

Our Pipeline 7

------

![Slide 8](lmnl-ex99_1s8.jpg)

Both our GPR84 antagonist and OXER1 antagonist are considered seven transmembrane G protein-coupled receptors (7TM GPCR's), the receptor protein passes through the cell membrane seven times. Around 35% of all approved drugs target GPCR's, and GPCR's are considered very "druggable"1 An agonist is a drug that binds to a target and mimics the action of the natural ligand An antagonist is a drug that binds to a receptor and prevents other molecules (such as the natural ligand) from binding Ligands are the natural agonist G proteins, also known as guanine nucleotide binding proteins, act as molecular switches inside cells and are involved in transmitting signals Multiple potential indications Building a pipeline of Antagonists 1Sriram K, Insel PA. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? Mol Pharmacol. 2018 Apr;93(4):251-258.

------

![Slide 9](lmnl-ex99_1s9.jpg)

Target Receptor for orphan GPC receptor GPR84 Rationale Blocks a proinflammatory modulator on immune cells, including macrophages, once inflammation is established1 Liminal IP Novel IP Potential Clinical Applications Many pro-inflammatory conditions2 such as: Inflammatory bowel disease (Crohn's Disease and Ulcerative Colitis) Idiopathic pulmonary fibrosis Non-alcoholic fatty liver disease (NAFLD)/ NASH Metabolic diseases (diabetes, glucose intolerance) GPR84 Antagonist with Numerous Potential Clinical Applications 1Recio, C, et al. Activation of the immune-metabolic receptor GPR84 enhances inflammation and phagocytosis in macrophages. Front Immunol 2018; 9: 1419; 2Marsango, S, et al. Therapeutic validation of an orphan G protein-coupled receptor: the case of GRP84. Br J Pharmacol 2022;179:3529-3541; Focused inflammatory disease targets support product in a pipeline development strategy 9

------

![Slide 10](lmnl-ex99_1s10.jpg)

GPR84: Role in Inflammation and Fibrosis ROS = Reactive oxygen species = GPR84 = agonist Neutrophil Monocyte/Macrophage Pro-inflammatory/ Pro-fibrotic Activity GPR84 Agonists Pro-inflammatory cytokines Oxidative burst / ROS Chemotaxis Inflammatory conditions increase GPR84 expression

------

![Slide 11](lmnl-ex99_1s11.jpg)

Next Steps for GPR84 Antagonist Program Based on the data from development work so far, we have nominated our lead preclinical drug candidate for our GRPR84 Antagonist program, LMNL6511. LMNL6511 Properties Low molecular weight Highly selective: no significant off-target liabilities noted in the comprehensive 169-target SpectrumScreen™ panel Next steps Subject to continued satisfactory results in ongoing clinical trial application (CTA)-enabling work, we expect to seek approval to commence a first-in-human Phase 1 clinical trial of LMNL6511 during 2023. On-going In-vivo experiments are expected to allow us to select our initial target indication for this lead preclinical drug candidate in the coming months.

------

![Slide 12](lmnl-ex99_1s12.jpg)

OXER1 Antagonist 12

------

![Slide 13](lmnl-ex99_1s13.jpg)

Target Receptor for inflammatory mediator 5-oxo-ETE Rationale Blocks potent proinflammatory mediator on eosinophils1 Liminal IP Novel IP Potential Clinical Applications Numerous acute and chronic allergic, inflammatory, and proliferative disease mediated by eosinophils2, such as: Severe eosinophilic asthma Atopic dermatitis Eosinophilic gastritis/gastroenteritis Eosinophilic esophagitis Allergic conjunctivitis OXER1 Antagonist with Numerous Clinical Applications 1Recio, C, et al. Activation of the immune-metabolic receptor GPR84 enhances inflammation and phagocytosis in macrophages. Front Immunol 2018; 9: 1419; 2Marsango, S, et al. Therapeutic validation of an orphan G protein-coupled receptor: the case of GRP84. Br J Pharmacol 2022;179:3529-3541; Focused inflammatory disease targets support product in a pipeline development strategy 13

------

![Slide 14](lmnl-ex99_1s14.jpg)

OXER1: Role in Tissue Repair and Inflammation 1. Gail et al, 2009 What is the OXER1 Receptor? OXER1 is a GPCR receptor which is mainly expressed in inflammatory cells. OXER1 is highly selective for 5-oxo-ETE, one of the most powerful chemo-attractants and activators of eosinophils. Why are eosinophils important? Eosinophils themselves are key in mounting an appropriate immune response against pathogens. When activated, they release a cocktail of toxic proteins along with cytokines to attract other immune cells all designed to attack and damage the pathogen. However, when eosinophils are chronically activated, these toxic proteins can also damage normal tissue and promote inflammation causing Eosinophilic-driven diseases What are the potential indications? Eosinophils are involved in acute and chronic inflammation and play an important role in a large number of allergic, inflammatory and proliferative diseases. 14

------

![Slide 15](lmnl-ex99_1s15.jpg)

OXER1 Potential To Treat Eosinophilic-Driven Disease Gastrointestinal Diseases Respiratory Diseases Other Diseases Skin Diseases Eosinophils are involved in acute and chronic inflammation and play an important role in a large number of allergic, inflammatory and proliferative diseases. Both eosinophils and mast cells are involved in the pathology of many of these diseases, including: Respiratory and Inflammatory Disease: Severe eosinophilic asthma COPD Hypereosinophilic syndrome (HES) Nasal polyposis Atopic dermatitis Chronic spontaneous urticaria Gastrointestinal Disease: Eosinophilic gastritis Eosinophilic esophagitis (EoE) Eosinophilic gastroenteritis

------

![Slide 16](lmnl-ex99_1s16.jpg)

Development Rationale & Opportunities in Eosinophil-related Diseases There are many drug development approaches to limit eosinophil-related tissue damage Eosinophil-targeting biology proven with existing, approved, monoclonal antibody drugs Reducing eosinophil levels shown to improve outcomes in severe asthma Blood eosinophil levels offer an easy-to-measure biomarker for early-stage clinical studies Despite existing competitor products in eosinophilic asthma, there is still an opportunity for an effective, small-molecule drug Not many competitor drugs in clinical-stage development for eosinophilic diseases No known competitors identified targeting the 5-oxo-ETE / OXE receptor: it's an entirely novel approach Preclinical candidate nomination expected in 2023. \*Image adapted from: https://www.immunology.org/public-information/bitesized-immunology/cells/eosinophils

------

![Slide 17](lmnl-ex99_1s17.jpg)

Opportunity to expand pipeline to study additional diversified candidates from the in-house discovery engine (over 3,000 compounds already generated). In-House Drug Discovery Engine Potential for in-house compounds to be augmented by in-licensed compounds. In-Licensed Compounds Potential to enter into strategic partnering or out-licensing opportunities for our programs with the potential of bringing in upfront and milestone payments to add to our cash runway. Collaborations Potential Expansion of R&D Portfolio We have a deep understanding of certain biological targets and pathways that have been implicated in the inflammatory and fibrotic process, including G-protein-coupled receptors.

------

![Slide 18](lmnl-ex99_1s18.jpg)

Business Summary 18

------

![Slide 19](lmnl-ex99_1s19.jpg)

Data Driven Execution and Delivery Expected Program Milestones GPR84 Antagonist Program 2023: Pre-clinical candidate selection and guidance on potential target disease areas 2023: Commence IND/CTA enabling studies for regulatory approval of clinical trial 2023: Regulatory submission for Phase 1 clinical trial 2023: Commence first-in-human clinical trial OXER1 Antagonist Program H1 2023: Pre-clinical candidate selection and guidance on potential target disease areas 2023: Commence IND/CTA enabling studies for regulatory approval of clinical trial 2024: Regulatory submission for Phase 1 clinical trial 2024: Commence first-in-human clinical trial 19

------

![Slide 20](lmnl-ex99_1s20.jpg)

Data Driven Execution and Delivery Potential Business Opportunities Drug Discovery Platform 2023: Opportunity to expand pipeline to study additional candidates with novel targets and novel pathways from in-house discovery engine, in-licenced compounds, or strategic partnering or out-licensing opportunities for our programs with the potential of bringing in upfront and milestone payments to add to our cash runway. Business Updates 2023: Continue to actively seek opportunities to monetize non-core assets, seek strategic partnerships, and further reduce costs. 20

------

![Slide 21](lmnl-ex99_1s21.jpg)

All figures presented in this section are in Canadian dollars unless otherwise specified. Executive Summary Cash as of December 31, 2022 just over $37M Potential development opportunities from in-house drug discovery platform Ongoing opportunity to monetise non-core assets Access to NASDAQ Market: LMNL Debt free Company with IP all under the control of Liminal 21 Current cash runway is anticipated to support our near-term development goals into early 2024.